With great power comes great vulnerability
The clinical responses to targeted drugs are often transient and do not always translate into meaningful overall survival due to the development of resistance. We discuss here that the greater power of drug resistant cells can be associated with significant newly-acquired vulnerabilities that can be exploited therapeutically.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Molecular & cellular oncology - 5(2018), 6 vom: 29., Seite e1509488 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Leite de Oliveira, Rodrigo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRAF |
|---|
| Anmerkungen: |
Date Revised 01.10.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1080/23723556.2018.1509488 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM291554016 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM291554016 | ||
| 003 | DE-627 | ||
| 005 | 20231225071125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/23723556.2018.1509488 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0971.xml |
| 035 | |a (DE-627)NLM291554016 | ||
| 035 | |a (NLM)30525088 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Leite de Oliveira, Rodrigo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a With great power comes great vulnerability |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.10.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The clinical responses to targeted drugs are often transient and do not always translate into meaningful overall survival due to the development of resistance. We discuss here that the greater power of drug resistant cells can be associated with significant newly-acquired vulnerabilities that can be exploited therapeutically | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BRAF | |
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a histone deacetylase inhibitor | |
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a reactive oxygen species | |
| 700 | 1 | |a Wang, Liqin |e verfasserin |4 aut | |
| 700 | 1 | |a Bernards, Rene |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular & cellular oncology |d 2014 |g 5(2018), 6 vom: 29., Seite e1509488 |w (DE-627)NLM245054391 |x 2372-3556 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2018 |g number:6 |g day:29 |g pages:e1509488 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/23723556.2018.1509488 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2018 |e 6 |b 29 |h e1509488 | ||